IMMU Immunomedics Inc.

17.3
+0.39  (+2%)
Previous Close 16.91
Open 16.81
Price To Book 28.83
Market Cap 3,321,226,908
Shares 191,978,434
Volume 461,913
Short Ratio
Av. Daily Volume 1,917,743

NewsSee all news

  1. Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  2. Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (OTC:MGTI), First American Financial Corporation (NYSE:FAF),

  3. Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  4. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQGM: IMMU) filed a class action complaint against the company for alleged violations of the Securities

  5. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SACITUZUMAB GOVITECAN
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.
SACITUZUMAB GOVITECAN
Urothelial cancer
CRL issued January 17, 2019. NDA to be refiled 4Q 2019.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus
Phase 3 trial has been initiated.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-02
HR+/HER2- metastatic breast cancer
Phase 1/2 interim data to be presented at ESMO September 28, 2019.
SACITUZUMAB GOVITECAN - TROPHY U-01
Urothelial cancer
Phase 1/2 trial underway.
Lucitanib with Rubraca (SEASTAR)
Ovarian cancer
Phase 2 trial has been initiated.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-03
Solid tumors
Phase 2 data due mid-2020.
SACTUZUMAB GOVITECAN (IMMU-132) - ASCENT
Cancer - metastatic triple-negative breast cancer

Latest News

  1. Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  2. Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (OTC:MGTI), First American Financial Corporation (NYSE:FAF),

  3. Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  4. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQGM: IMMU) filed a class action complaint against the company for alleged violations of the Securities

  5. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today